Clinical Trial Update: Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating whether caffeine affects regadenoson administration during SPECT myocardial perfusion imaging in coronary artery disease, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Caffeine (caffeine)
• Lexiscan (regadenoson)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Coronary Artery Disease (CAD) | Phase 3 | Status: COMPLETED | Results posted: 2011-10-21